Publications by authors named "John Feaster"

Claim this Profile
C
CSL112 (Apolipoprotein A-I [Human]) Reduces the Elevation in Neutrophil-to-Lymphocyte Ratio Induced by Acute Myocardial Infarction.
Bronwyn A Kingwell, Danielle Duffy, Regina Clementi, Elena Velkoska, John Feaster

J Am Heart Assoc· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison.
Bo Zheng, Shinya Goto, Regina Clementi, John Feaster, Danielle Duffy

Clin Transl Sci· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.
Michael A Tortorici, Danielle Duffy, Rebecca Evans, John Feaster, Andreas Gille

Clin Pharmacol Drug Dev· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
C Michael Gibson, Mathieu Kerneis, Megan K Yee, Yazan Daaboul, Serge Korjian, John Feaster

Am Heart J· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dihydronepetalactones deter feeding activity by mosquitoes, stable flies, and deer ticks.
John E Feaster, Mark A Scialdone, Robin G Todd, Yamaira I Gonzalez, Joseph P Foster

J Med Entomol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis